Literature DB >> 15254429

Medulloblastoma and retinoblastoma: oncology recapitulates ontogeny.

Justyna T Romer1, Thomas Curran.   

Abstract

One major factor hindering progress of pediatric cancers of the nervous system has been the lack of satisfactory model systems for testing novel therapies. A mouse strain, mutant for the Rb1 gene was generated 12 years ago in the hope of producing a model in which to study retinoblastoma. Surprisingly, the Rb(+/-) mice never developed retinoblastoma. Now, Zhang, Schweers and Dyer produce triply deficient Rb, p107 and p53 mutant retinal progenitor cells. All such mice develop intraocular retinoblastoma with invasion of the tumor into the anterior chamber of the eye. This dramatic finding represents the first description of a heritable mouse model of retinoblastoma, which has eluded investigators for the last 12 years. Such models provide an unprecedented opportunity to advance knowledge of tumorigenesis and to develop non-toxic intervention strategies which eradicate disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254429

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  3 in total

Review 1.  Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing.

Authors:  Nathalie Cassoux; Aurélie Thuleau; Franck Assayag; Isabelle Aerts; Didier Decaudin
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

2.  A small-molecule smoothened agonist prevents glucocorticoid-induced neonatal cerebellar injury.

Authors:  Vivi M Heine; Amelie Griveau; Cheryl Chapin; Philip L Ballard; James K Chen; David H Rowitch
Journal:  Sci Transl Med       Date:  2011-10-19       Impact factor: 17.956

3.  Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.

Authors:  Giulia Gentile; Manuela Ceccarelli; Laura Micheli; Felice Tirone; Sebastiano Cavallaro
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.